Rare diseases
Investigational molecules
Locations
8 Rue De La Croix Jarry, 75013 Paris, France
Cellectis focuses on clinical research in aggressive blood cancers, with activity centered on relapsed and refractory disease. The sponsor’s studies address B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma, reflecting a therapeutic interest in difficult-to-treat malignancies of the lymphoid system.
The clinical program includes patients whose disease has persisted after prior treatment, including those with prior CD19-directed therapy.
Cellectis runs clinical trials in conditions such as B-cell lymphoma, B-cell lymphoma refractory, B-cell type acute leukaemia, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
FranceFranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
